Trevi Therapeutics (TRVI) Net Cash Flow (2018 - 2026)

Trevi Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at $498000.0 in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 103.38% year-over-year to $498000.0; the trailing twelve-month figure through Mar 2026 stood at $38000.0 (down 99.32% YoY), and the FY2025 full-year result was -$15.2 million, down 993.12% from the prior year.
• Net Cash Flow for Q1 2026 stood at $498000.0, up from -$38.0 million in the prior quarter.
• The five-year high for Net Cash Flow was $97.7 million in Q2 2025, with the low at -$60.2 million in Q3 2025.
• Average Net Cash Flow over 5 years is $2.2 million, with a median of $498000.0 recorded in 2026.
• Peak annual rise in Net Cash Flow reached 11619.34% in 2025, while the deepest fall reached 2048.49% in 2025.
• Tracing TRVI's Net Cash Flow over 5 years: stood at -$54.0 million in 2022, then surged by 111.91% to $6.4 million in 2023, then jumped by 180.55% to $18.0 million in 2024, then sank by 310.34% to -$38.0 million in 2025, then surged by 101.31% to $498000.0 in 2026.
• The last three Net Cash Flow figures came in at $498000.0 (Q1 2026), -$38.0 million (Q4 2025), and -$60.2 million (Q3 2025), per Business Quant data.

Peer Comparison